West Pharmaceutical Services, Inc. (NYSE:WST) Shares Purchased by IFM Investors Pty Ltd

IFM Investors Pty Ltd increased its position in shares of West Pharmaceutical Services, Inc. (NYSE:WSTFree Report) by 1.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 14,451 shares of the medical instruments supplier’s stock after purchasing an additional 178 shares during the quarter. IFM Investors Pty Ltd’s holdings in West Pharmaceutical Services were worth $5,088,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Sunbelt Securities Inc. acquired a new position in West Pharmaceutical Services in the first quarter valued at approximately $25,000. RVW Wealth LLC acquired a new position in West Pharmaceutical Services in the third quarter valued at approximately $38,000. First Horizon Advisors Inc. lifted its holdings in West Pharmaceutical Services by 37.4% in the first quarter. First Horizon Advisors Inc. now owns 147 shares of the medical instruments supplier’s stock valued at $51,000 after acquiring an additional 40 shares during the period. International Assets Investment Management LLC acquired a new position in West Pharmaceutical Services in the third quarter valued at approximately $53,000. Finally, Addison Advisors LLC lifted its holdings in West Pharmaceutical Services by 37.9% in the third quarter. Addison Advisors LLC now owns 142 shares of the medical instruments supplier’s stock valued at $53,000 after acquiring an additional 39 shares during the period. 91.23% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other West Pharmaceutical Services news, SVP Silji Abraham sold 7,012 shares of the stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $365.00, for a total value of $2,559,380.00. Following the sale, the senior vice president now owns 4,660 shares of the company’s stock, valued at approximately $1,700,900. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other West Pharmaceutical Services news, CEO Eric Mark Green sold 64,132 shares of the stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $359.85, for a total value of $23,077,900.20. Following the sale, the chief executive officer now owns 152,908 shares of the company’s stock, valued at approximately $55,023,943.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Silji Abraham sold 7,012 shares of the stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $365.00, for a total value of $2,559,380.00. Following the completion of the sale, the senior vice president now directly owns 4,660 shares in the company, valued at approximately $1,700,900. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 73,978 shares of company stock valued at $26,653,772. Corporate insiders own 1.13% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently weighed in on WST. StockNews.com downgraded West Pharmaceutical Services from a “buy” rating to a “hold” rating in a research note on Friday, February 16th. Jefferies Financial Group upgraded West Pharmaceutical Services from a “hold” rating to a “buy” rating and boosted their price target for the stock from $323.00 to $536.00 in a research report on Wednesday, February 7th. UBS Group dropped their price target on West Pharmaceutical Services from $400.00 to $375.00 and set a “neutral” rating for the company in a research report on Friday, February 16th. Finally, KeyCorp upped their target price on West Pharmaceutical Services from $440.00 to $470.00 and gave the company an “overweight” rating in a report on Tuesday, February 13th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, West Pharmaceutical Services currently has an average rating of “Moderate Buy” and a consensus target price of $435.20.

Check Out Our Latest Analysis on WST

West Pharmaceutical Services Stock Performance

Shares of West Pharmaceutical Services stock opened at $393.92 on Friday. West Pharmaceutical Services, Inc. has a 52 week low of $310.42 and a 52 week high of $415.73. The business’s fifty day simple moving average is $371.62 and its 200-day simple moving average is $364.20. The firm has a market cap of $28.84 billion, a PE ratio of 49.99, a price-to-earnings-growth ratio of 7.08 and a beta of 1.03. The company has a quick ratio of 2.24, a current ratio of 2.88 and a debt-to-equity ratio of 0.03.

West Pharmaceutical Services (NYSE:WSTGet Free Report) last posted its earnings results on Thursday, February 15th. The medical instruments supplier reported $1.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.78 by $0.05. West Pharmaceutical Services had a return on equity of 21.60% and a net margin of 20.12%. The firm had revenue of $732.00 million for the quarter, compared to analyst estimates of $740.43 million. During the same quarter in the prior year, the company earned $1.77 EPS. West Pharmaceutical Services’s revenue was up 3.3% on a year-over-year basis. Equities analysts forecast that West Pharmaceutical Services, Inc. will post 7.62 earnings per share for the current year.

West Pharmaceutical Services Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Investors of record on Wednesday, April 24th will be paid a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a yield of 0.20%. The ex-dividend date of this dividend is Tuesday, April 23rd. West Pharmaceutical Services’s payout ratio is 10.15%.

About West Pharmaceutical Services

(Free Report)

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.

See Also

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WSTFree Report).

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.